Bone Marrow Monocytes Research Articles

Monocyte priming during acute myocardial infarction alterations of the bone marrow monocyte reservoir secondary to myocardial infarction

Monocyte priming during acute myocardial infarction alterations of the bone marrow monocyte reservoir secondary to myocardial infarction

Clodronate is not protective in lethal viral encephalitis despite substantially reducing inflammatory monocyte infiltration in the CNS.

Bone marrow (BM)-derived monocytes induce inflammation and tissue damage in a range of pathologies. In particular, in a mouse model of West Nile virus (WNV) encephalitis (WNE), nitric oxide-producing, Ly6Chi inflammatory monocytes from the BM are recruited to the central nervous system (CNS) and contribute to lethal immune pathology. Reducing the migration of these cells into the CNS using monoclonal antibody blockade, immune-modifying particles or CSF-1R inhibitors reduces neuroinflammation, improving survival and/or clinical outcomes. Macrophages can also be targeted more broadly by administration of clodronate-encapsulated liposomes, which induce apoptosis in phagocytes. In this study, clodronate reduced the inflammatory infiltrate by 70% in WNE, however, surprisingly, this had no effect on disease outcome. More detailed analysis demonstrated a compensatory increase in neutrophils and enhanced activation status of microglia in the brain. In addition, we observed increased numbers of Ly6Chi BM monocytes with an increased proliferative capacity and expression of SCA-1 and CD16/32, potentially indicating output of immature cells from the BM. Once in the brain, these cells were more phagocytic and had a reduced expression of antigen-presenting molecules. Lastly, we show that clodronate also reduces non-myeloid cells in the spleen and BM, as well as ablating red blood cells and their proliferation. These factors likely impeded the therapeutic potential of clodronate in WNE. Thus, while clodronate provides an excellent system to deplete macrophages in the body, it has larger and broader effects on the phagocytic and non-phagocytic system, which must be considered in the interpretation of data.

LPS priming before plaque deposition impedes microglial activation and restrains Aβ pathology in the 5xFAD mouse model of Alzheimer’s disease

Microglia have an innate immunity memory (IIM) with divergent functions in different animal models of neurodegenerative diseases, including Alzheimer’s disease (AD). AD is characterized by chronic neuroinflammation, neurodegeneration, tau tangles and β-amyloid (Aβ) deposition. Systemic inflammation has been implicated in contributing to the progression of AD. Multiple reports have demonstrated unique microglial signatures in AD mouse models and patients. However, the proteomic profiles of microglia modified by IIM have not been well-documented in an AD model. Therefore, in the present study, we investigate whether lipopolysaccharide (LPS)-induced IIM in the pre-clinical stage of AD alters the microglial responses and shapes the neuropathology. We accomplished this by priming 5xFAD and wild-type (WT) mice with an LPS injection at 6 weeks (before the robust development of plaques). 140 days later, we evaluated microglial morphology, activation, the microglial barrier around Aβ, and Aβ deposition in both 5xFAD primed and unprimed mice. Priming induced decreased soma size of microglia and reduced colocalization of PSD95 and Synaptophysin in the retrosplenial cortex. Priming appeared to increase phagocytosis of Aβ, resulting in fewer Thioflavin S+ Aβ fibrils in the dentate gyrus. RIPA-soluble Aβ 40 and 42 were significantly reduced in Primed-5xFAD mice leading to a smaller size of MOAB2+ Aβ plaques in the prefrontal cortex. We also found that Aβ-associated microglia in the Primed-5xFAD mice were less activated and fewer in number. After priming, we also observed improved memory performance in 5xFAD. To further elucidate the molecular mechanism underlying these changes, we performed quantitative proteomic analysis of microglia and bone marrow monocytes. A specific pattern in the microglial proteome was revealed in primed 5xFAD mice. These results suggest that the imprint signatures of primed microglia display a distinctive phenotype and highlight the potential for a beneficial adaption of microglia when intervention occurs in the pre-clinical stage of AD.

CD73 Dysregulates Monocyte Anti-Tumor Activity in Multiple Myeloma.

Multiple myeloma (MM) is characterized by immune cell dysfunction in the tumor microenvironment (TME). We aimed at evaluating the effect of CD73, an overexpressed factor in some tumors, on anti-tumor immune function in the TME of MM. We analyzed the expression of CD73 in T-, B-, and natural killer (NK)-lymphocytes and monocytes in bone marrow (BM), peripheral blood (PB) from MM patients and healthy controls, and residual CD138+ cells using flow cytometry. The anti-tumor activity of these monocytes was confirmed by co-culture with RPMI-8226 cells treated with a CD73 inhibitor. We determined the interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ levels using a cytometric bead array. Monocyte phagocytosis in cell culture sediment was then observed and measured. CD73 was highly expressed in T-, B-, and NK-lymphocytes and monocytes from the BM and PB isolated from patients with MM. Compared with healthy controls, MM samples exhibited significantly higher CD73 expression and TNF-α, IFN-γ, IL-10 levels in monocytes. Inhibiting CD73 in BM immune cells from MM samples significantly increased the secretion of IL-2, TNF-α, and IFN-γ, as well as the killing ability of immune cells. However, monocyte phagocytosis was seldom observed. Inhibiting CD73 in MM monocytes significantly increased the secretion of IL-2, TNF-α, and IFN-γ in monocytes and improved monocyte killing and phagocytosis. Monocytes from MM exhibited weakened anti-tumor effects, and CD73 was involved in forming an immunosuppressive microenvironment. Inhibiting CD73 partly restored the anti-tumor activity of monocytes, a potential strategy for the treatment of MM.

Low-intensity pulsed ultrasound regulates osteoblast-osteoclast crosstalk via EphrinB2/EphB4 signaling for orthodontic alveolar bone remodeling.

Background: The limited regenerative potential of periodontal tissue remains a challenge in orthodontic treatment, especially with respect to alveolar bone remodeling. The dynamic balance between the bone formation of osteoblasts and the bone resorption of osteoclasts controls bone homeostasis. The osteogenic effect of low-intensity pulsed ultrasound (LIPUS) is widely accepted, so LIPUS is expected to be a promising method for alveolar bone regeneration. Osteogenesis is regulated by the acoustic mechanical effect of LIPUS, while the cellular perception, transduction mode and response regulation mechanism of LIPUS stimuli are still unclear. This study aimed to explore the effects of LIPUS on osteogenesis by osteoblast-osteoclast crosstalk and the underlying regulation mechanism. Methods: The effects of LIPUS on orthodontic tooth movement (OTM) and alveolar bone remodeling were investigated via rat model by histomorphological analysis. Mouse bone marrow mesenchymal stem cells (BMSCs) and bone marrow monocytes (BMMs) were purified and used as BMSC-derived osteoblasts and BMM-derived osteoclasts, respectively. The osteoblast-osteoclast co-culture system was used to evaluate the effect of LIPUS on cell differentiation and intercellular crosstalk by Alkaline phosphatase (ALP), Alizarin Red S (ARS), tartrate-resistant acid phosphatase (TRAP) staining, real-time quantitative PCR, western blotting and immunofluorescence. Results: LIPUS was found to improve OTM and alveolar bone remodeling in vivo, promote differentiation and EphB4 expression in BMSC-derived osteoblasts in vitro, particularly when cells were directly co-cultured with BMM-derived osteoclasts. LIPUS enhanced EphrinB2/EphB4 interaction between osteoblasts and osteoclasts in alveolar bone, activated the EphB4 receptor on osteoblasts membrane, transduced LIPUS-related mechanical signals to the intracellular cytoskeleton, and gave rise to the nuclear translocation of YAP in Hippo signaling pathway, thus regulating cell migration and osteogenic differentiation. Conclusions: This study shows that LIPUS modulates bone homeostasis by osteoblast-osteoclast crosstalk via EphrinB2/EphB4 signaling, which benefits the balance between OTM and alveolar bone remodeling.

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.

Background: A growing body of evidence has indicated impaired function or compositional changes of monocytes in inflammatory disorders, such as acute respiratory syndrome and covid-19. In myeloma tumor microenvironment, activation of type I interferon pathway and dysregulated expression of major histocompatibility complex type II genes are observed in classical monocytes, which result in loss of antigen presentation of monocytes. The proportions of BAFF+PD-L1+ monocytes in the bone marrow also correlate with survival of myeloma patients following chimeric antigen-receptor T cell therapy. Nevertheless, the mechanisms underlying PB and BM monocytes defects in myeloma remain poorly addressed, at least in part by the lack of large scale scRNA-seq studies. To resolve the heterogeneous bone marrow and peripheral blood monocyte subpopulations and their transcriptional factors between healthy donors and multiple myeloma patients. Methods: We conducted scRNA-seq on monocytes of 7 newly diagnosed myeloma patients and 12 healthy donors. Specifically, 3 and 5 bone marrow aspirates and 9 and 7 peripheral blood samples of 12 healthy controls and 7 newly diagnosed patients were obtained, respectively. Results: Heterogeneous bone marrow and peripheral blood monocyte subpopulations and their transcriptional factors were resolved. The function characteristics of monocyte were compared between MM patients and healthy donors, which indicated a stress signature induced by multiple myeloma. Furthermore, we identified two monocyte differentiation pathways, and discovered that bone marrow monocyte feature type I IFN-associated differentiation dysregulation in patients with MM as well as dysregulated patterns at transcriptome. Finally, we included 10 MM patients as a validation cohort, by tracking the stress signature over time in those patients undergoing first-line treatment, we founded that the stress signature was partially overcome by antitumor therapy. Conclusion: Our results provided further insight into transcriptional and differentiation changes occurring in the bone marrow and peripheral blood monocytes from patients with multiple myeloma and hint and mechanisms of immune evasion. Encore Abstract - previously submitted to EHA 2023 The research was funded by: This investigation was supported by the International Cooperation Projects of National Natural Science Foundation (grants 81920108006), CAMS Innovation Fund for Medical Sciences (CIFMS) (grants 2022-I2M-1-022), the National Natural Science Foundation (grants 81630007; grants 82270218, 81670202; grants 81900214), and the Atlas of Blood Cell Alliance. Keywords: genomics, epigenomics, and other -omics, microenvironment, multiple myeloma No conflicts of interests pertinent to the abstract.

Origin of Osteoclasts: Osteoclast Precursor Cells.

Osteoclasts are multinucleated bone-resorbing cells and a key player in bone remodeling for health and disease. Since the discovery of osteoclasts in 1873, the structure and function of osteoclasts and the molecular and cellular mechanisms of osteoclastogenesis have been extensively studied. Moreover, it has been well established that osteoclasts are differentiated in vitro from myeloid cells such as bone marrow macrophages or monocytes. The concept showing that osteoclasts are derived from a specific population (named osteoclast precursor cells [OCPs]) among myeloid cells has been long hypothesized. However, the specific precursor population of osteoclasts is not clearly defined yet. A growing body of work provides evidence of the developmental origin and lifespan of murine osteoclasts, particularly in vivo. Here, we review the emerging evidence that supports the existence of OCPs and discuss current insights into their identity.

Abstract 163: Thrombocytopenia Independently Leads To Monocyte Immune Dysfunction

In addition to their well-studied hemostatic functions, platelets are immune cells. Platelets circulate at the interface between the vascular wall and leukocytes, and transient platelet-leukocyte complexes are found in both healthy and disease states, positioning platelets to provide physiologic cues of both vascular health and injury. Roles for activated platelets in inducing and amplifying immune responses have received an increasing amount of research attention, but our past studies also showed that normal platelet counts are needed in healthy conditions to maintain immune homeostasis. We have now found that thrombocytopenia (a low platelet count) leads to monocyte dysfunction, independent of the cause of thrombocytopenia, in a manner that is dependent on direct platelet-monocyte CD47 interactions that regulate monocyte immunometabolism and gene expression. Compared to monocytes from mice with normal platelet counts, monocytes from thrombocytopenic mice had increased toll-like receptor (TLR) responses, including increased IL-6 production. Furthermore, ex vivo co-incubation of resting platelets with platelet naïve bone marrow monocytes, induced monocyte metabolic programming and durable changes in TLR agonist responses. Assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-Seq) on monocytes from thrombocytopenic mice showed persistently open chromatin at LPS response genes. Using mouse models of thrombocytopenia and sepsis we found that normal platelet numbers are needed to limit immune dysregulation in sepsis. IL6 and TNF expression in monocytes from human patients with sepsis also inversely correlated with patient platelet counts. Our studies demonstrate that in healthy conditions resting platelets maintain monocyte immune tolerance by regulating monocyte immunometabolic processes that lead to epigenetic changes in TLR-related genes. Platelets therefore function as immune rheostats in both health and disease.

Abstract A14: Ex vivo immune activation with the macrophage-targeting immunotherapy, anti-Clever-1 antibody bexmarilimab, in acute myeloid leukemia and myelodysplastic syndrome

Abstract The potential of immunotherapies in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains still under investigation. Clever-1 (also known as Stabilin-1) is a multifunctional scavenger and adhesion receptor expressed by monocytes and immunosuppressive macrophages. Bexmarilimab, a Clever-1 targeting antibody, demonstrates many immunomodulatory effects1 along with promising anti-tumor activity against solid tumors in patients with multiple lines of previous treatment2. In AML, high STAB1 (mRNA) levels associate with poor survival and resistance to therapy3. The aim of this study was to profile Clever-1 expression in AML and MDS and test in preclinical models the growth inhibitory and immunomodulatory potential of bexmarilimab, as a single agent and in combination with azaciditine and venetoclax. AML cell lines (n=11) and frozen mononuclear cells, extracted from AML (n=42) and very high risk MDS (n=4) patient bone marrow (BM) aspirates provided by the Finnish Hematology Registry and Biobank, were used. Samples were treated for 48h with bexmarilimab alone, or in combination with azacytidine and/or venetoclax. Flow cytometry was used to detect different myeloid and TBNK cell populations along with Clever-1, HLA-DR, PD-(L)1 and additional T cell activation markers. Our results confirmed Clever-1 protein expression in AML cell lines and bexmarilimab treatment induced metabolic and growth inhibition of KG1 blasts (Clever-1high). In patients with AML, FAB M4/M5 subtypes exhibited highest Clever-1 levels, along with FAB M2 patients with consequent rapid relapse. Clever-1 expression correlated negatively with monocyte MHC class II molecule, HLA-DR, expression, and BM T-cell frequency, in line with the immunosuppressed state associated with high Clever-1. Ex vivo treatment of the primary AML BM cells with bexmarilimab resulted in a notable, 5-10x fold increase in monocyte HLA-DR in samples with low basal HLA-DR and high Clever-1. The combination of azacitidine with bexmarilimab augmented HLA-DR induction by 20-110% (mean 44%). FAB M1/M2 AML showed increase in activation markers, such as Ki67, CXCR3 and Granzyme B after ex vivo bexmarilimab treatment in CD8+ T-cells. Furthermore, bexmarilimab reduced PD-1 expression in NK- and CD8+CXCR3+ T-cell populations of FAB M0-M2 AML and MDS-EB2. This project is the first comprehensive investigation of Clever-1 expression in AML and MDS patient BM blasts and monocytes. Ex vivo treatment with bexmarilimab, alone or in combination with azacytidine or venetoclax, indicate enhanced antigen presentation capability and immunological activation. These results validate the therapeutic potential of bexmarilimab in myeloid malignancies. The safety, tolerability and preliminary efficacy of bexmarilimab is now further investigated in combination with venetoclax and/or azacytidine in a phase I/II clinical trial BEXMAB (NCT05428969).1Viitala et al., Clin Cancer Res 2019;25:3289-303; 2 Bono et al., Annals of Oncology; 2021. p 32, 5: S1283-S346; 3 Lin et al., Mol Ther Nucleic Acids 2019;18:476-84 Citation Format: Arno Ylitalo, Sofia Aakko, Heikki Kuusanmäki, Mari Björkman, Juho Jalkanen, Marie-Louise Fjällskog, Caroline Heckman, Maija Hollmén, Mika Kontro. Ex vivo immune activation with the macrophage-targeting immunotherapy, anti-Clever-1 antibody bexmarilimab, in acute myeloid leukemia and myelodysplastic syndrome [abstract]. In: Proceedings of the AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome; 2023 Jan 23-25; Austin, TX. Philadelphia (PA): AACR; Blood Cancer Discov 2023;4(3_Suppl):Abstract nr A14.

Abstract 160: Atherosclerosis Regression At The Single-Cell Level

Atherosclerosis is a chronic inflammatory disease, but lipid-lowering therapies continue to be the standard of care, and substantial regression of human atheromata remains an elusive goal. To address this gap, our lab has devised multiple models to achieve plaque regression in atherosclerotic mice using genetic or RNA-based approaches. Here, we set out to learn how the immune cell composition of murine plaques changes with the induction of a regression phenotype irrespective of model. To achieve this, we performed single cell RNA-seq on CD45 + leukocytes from the aortic arch plaques of Ldlr -/- mice fed an atherogenic diet (baseline progression) and from two additional cohorts that were switched to control chow following atherogenesis and either treated with antisense oligonucleotides targeting ApoB (regression) or not (halted progression). The resultant transcriptomic data were integrated with those from our previous regression studies in a batch-corrected manner to distill the common features of atherosclerosis regression. This approach yielded a dataset of 35,996 cells, a degree of granularity one order of magnitude higher than that of the average comparable study, which allowed us to draw a comprehensive picture of the lymphoid and myeloid transcriptional dynamics that give rise to pro-resolving phenotypes. Specifically, we found two novel macrophage populations with distinct transcriptional profiles and unique distribution across conditions that nonetheless shared the same differentiation path. The first was characteristic of the halted progression groups and showed upregulation of genes involved in oxidative phosphorylation; the other was enriched in regression and displayed a transcriptional program consistent with plaque remodeling by means of efferocytosis and cholesterol efflux. Our findings suggest that pro-resolving macrophage fate acquisition in regression occurs at the expense of a separate, potentially pro-inflammatory lineage. A deeper understanding of the molecular and cellular purview of these pro-resolving macrophages as well as the ontogenic path of bone marrow monocytes toward that fate would contribute to the development of anti-inflammatory therapies to treat and prevent atherosclerosis.

A novel Fth1-mScarlet reporter mouse supports quantification of monocyte-derived macrophage inflammatory state in vivo

Abstract Monocyte-derived macrophages (mo-macs) acquire a spectrum of pro- and anti-inflammatory functions during infection-associated inflammation and resolution. Quantification of mo-mac functional state is critical to elucidate mechanisms leading to dysregulation of inflammatory control and how these processes can be manipulated therapeutically. Given that binary M1/M2 cell markers often fail to explain macrophage function in vivo, we sought to identify genes predictive of inflammatory gene signatures. We analyzed published single cell RNAseq of macrophages during lung inflammation, using Lasso (L1-penalized linear regression) to weight genes according to their ability to predict all other genes, and identified Fth1 (Ferritin Heavy Chain 1) as the most predictive gene. We generated Fth1-mScarlet reporter mice using CRISPR/Cas9 technology, inserting mScarlet in-frame of Fth1, linked through a T2A self-cleaving peptide. Using live cell imaging in vitro, we found monocyte mScarlet expression peaked 24 hours after stimulation with S. aureus or TLR ligands. We are currently using monocyte adoptive transfer to track mo-mac fate during acute S. aureus lung infection. In this intra-nasal S. aureus model (strain FDA309), pro-inflammatory genes and infiltration of neutrophils and monocytes peak 1–2 days post infection. We transferred Fth1mScarlet bone marrow monocytes 6 hours after infection, analyzed their recruitment into the lungs, and quantified mScarlet expression over time. Increased mScarlet expression was associated with the transition of donor cells from Ly6C+CD11c-monocytes to Ly6C-CD11c+ mo-macs. This model will allow us to quantify the plasticity and persistence of mo-macs during inflammation and resolution. R35 GM146896 (PI - Gottschalk)

BCG component mycolic acid protects against monocyte exhaustion in vitro

Abstract Monocyte exhaustion reflected in pathogenic inflammation and immune suppression underlies the pathogenesis of sepsis. The objective of this study is to define novel approaches in alleviating monocyte exhaustion, based on intriguing clinical reports that BCG components may be beneficial in reducing polymicrobial infection-triggered sepsis severity. We recapitulated in vitrothe development of exhausted murine monocytes through prolonged culture with high dose bacterial lipopolysaccharide (LPS), measured by the expansion of immature Ly6C hipopulation with elevated expression of pathogenic mediator CD38 and immune suppressor PD-L1, and reduced expression of CD86. Intriguingly, we observed that co-culture of murine bone marrow monocytes with Mycobacterium tuberculosis(BCG) component mycolic acid (MA) can significantly alleviate the development of exhausted monocytes. We found that monocytes co-stimulated with MA and LPS exhibited significantly reduced induction of CD38 and PD-L1 as compared to monocytes challenged with LPS alone. On the other hand, monocytes co-treated with MA and LPS exhibited enhanced expression of CD86 as compared to cells treated with LPS. In the monocyte-T cell coculture system, we found that T cells co-cultured with MA and LPS-treated monocytes had a significantly higher proliferation potential as compared to the T cells co-cultured with LPS-treated monocytes. Mechanically, we demonstrated that MA exerts its protective effect by selectively activating P-AKT and inhibiting STAT1/P-STAT1. In conclusion, we demonstrate that the BCG component mycolic acid can potently alleviate monocyte exhaustion and may serve as a future promising agent in treating sepsis. Supported by grants from NIH (AI136386)

Abstract 148: Lipoprotein Lipase Deficiency Reprograms Bone Marrow Cellular Metabolic Activity And Inflammatory Responses

Objectives: Activated bone marrow (BM) hematopoiesis is associated with systemic inflammation that increases risk for atherosclerosis. We had reported that lipoprotein lipase (LpL), in addition to being a lipolytic enzyme, regulated peripheral and tissue leukocyte levels and affected BM monocyte progenitor differentiation. LpL is mainly expressed in the specialized BM niches. We now questioned the role of LpL in influencing BM microenvironment that affects the homing and differentiation of hematopoietic stem/progenitor cells toward distinct lineages. Methods and Results: We characterized the metabolic and transcriptional phenotypes of BM cells utilizing immunofluorescence, flow cytometry, quantitative RT-PCR, and Seahorse Bioenergetics analysis in transgenic LpL knockout (KO) mice rescued by muscle-specific LpL expression. Differential gene expression (DEG) of BM cells were examined by bulk RNA sequencing (RNAseq). Our data indicate that LpL deficiency reduced expression of key BM vascular niche markers by 2-3-fold (p<0.05), including CD31, Tie-2, endomucin, CXCL12, and CXCR4, as well their associated growth factors - HIF-1α and VEGF. BM vascular endothelial cadherin-labeled cells were decreased by >50% (p<0.05) in LpL KO when compared to that in WT. Cellular uptake of chylomicron-size lipid particles was reduced in LpL KO BM, which may link to metabolic adaptation from mitochondrial oxidative phosphorylation towards glycolysis observed in LpL KO BM (p<0.05). Although the leptin-receptor positive perivascular cells were remained intact, expression of key lipolytic genes, such as ATGL, MGL, and LAL, were markedly reduced by >50% in LpL KO (p < 0.05). KEGG enrichment analysis of DEG shows that LpL KO BM cells had altered hematopoietic lineage signaling pathway. NFκB-directed signaling cascade was also downregulated in LpL KO BM cells, resulting in the reduced expression of pro-inflammatory TNF-α, IL-1β and IL-6. Conclusions: Our results indicate that LpL regulates metabolic activity and inflammatory responses of BM cells. A further understanding of these mechanisms will open the possibilities to target reprogram of both hematopoietic and BM niche cells as a therapeutic strategy to improve atherosclerosis-associated inflammation.

Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer

PurposeThe efficacy of immune checkpoint inhibitors such as programmed cell death ligand 1 (PD-L1) antibodies in non-small cell lung cancer (NSCLC) is limited, and combined use with other therapies is recommended. Dipeptidyl peptidase 4 (DPP4) inhibitors, a class of small molecule inhibitors, are highly effective for treating type 2 diabetes. Emerging evidence implicates DPP4 inhibitors as immunomodulators that modify aspects of innate and adaptive immunity. We evaluated the combination of a DPP4 inhibitor (anagliptin) and PD-L1 blockade in an NSCLC mouse model.MethodsThe effect of the combination of anti-PD-L1 and anagliptin was evaluated in subcutaneous mouse models of NSCLC. Tumor-infiltrating immune cells were analyzed by flow cytometry. Bone marrow-derived monocytes of C57BL/6 mice were isolated in vitro to examine the underlying mechanism of anagliptin on the differentiation and polarization of macrophage.ResultsAnagliptin dramatically improved the efficacy of PD-L1 antibody monotherapy by inhibiting macrophage formation and M2 polarization in the tumor microenvironment. Mechanistically, anagliptin suppressed the production of reactive oxygen species in bone marrow monocytes by inhibiting NOX1 and NOX2 expression induced by macrophage colony-stimulating factor, reduced late ERK signaling pathway activation, and inhibited monocyte-macrophage differentiation. However, the inhibitory effect was reactivated by lipopolysaccharide and interferon-gamma interacting with corresponding receptors during M1 macrophage polarization, but not M2.ConclusionsAnagliptin can enhance PD-L1 blockade efficacy in NSCLC by inhibiting macrophage differentiation and M2 macrophage polarization, and combination therapy may be a promising strategy for treating PD-L1 blockade therapy-resistant patients with NSCLC.

The histone demethylase KDM5C controls female bone mass by promoting energy metabolism in osteoclasts.

Women experience osteoporosis at higher rates than men. Aside from hormones, the mechanisms driving sex-dependent bone mass regulation are not well understood. Here, we demonstrate that the X-linked H3K4me2/3 demethylase KDM5C regulates sex-specific bone mass. Loss of KDM5C in hematopoietic stem cells or bone marrow monocytes increases bone mass in female but not male mice. Mechanistically, loss of KDM5C impairs the bioenergetic metabolism, resulting in impaired osteoclastogenesis. Treatment with the KDM5 inhibitor reduces osteoclastogenesis and energy metabolism of both female mice and human monocytes. Our report details a sex-dependent mechanism for bone homeostasis, connecting epigenetic regulation to osteoclast metabolism and positions KDM5C as a potential target for future treatment of osteoporosis in women.

Osteoclastogenesis of human peripheral blood, bone marrow, and cord blood monocytes

Osteoclasts are multinucleated bone resorbing cells that can be differentiated from human monocytes in vitro. There are few studies comparing osteoclastogenesis of different monocyte sources. We compared monocytes from human bone marrow (BM), peripheral blood (PB), and umbilical cord blood (CB) and their osteoclastogenic potential by culturing them with RANKL (20 and 80 ng/ml) and M-CSF (10 ng/ml) for 14 days. We also cultured cells without growth factors, as umbilical cord blood monocytes have been reported to be able to fuse spontaneously into osteoclasts. The data was analysed on d4, d8, d11, and d14. After culture with RANKL and M-CSF, all types of cell cultures developed TRACP -positive multinuclear cells that were able to form resorption pits on human bone slices. Only occasional multinuclear cells and small infrequent resorbed areas could be found in PB and CB-derived cultures without growth factors. BM-derived cells formed greater resorption areas than PB- and CB-derived monocytes. The greatest monocyte population in BM samples were intermediate (CD14++CD16+) and in PB and CB classical monocytes (76.3% and 54.4%, respectively). In conclusion, our data demonstrates that bone resorbing osteoclasts can be differentiated from BM, PB and CB. However, the osteoclast precursor origin can affect the osteoclast properties and function.

Safranal inhibits estrogen-deficiency osteoporosis by targeting Sirt1 to interfere with NF-κB acetylation

BackgroundOsteoporosis is a prevalent bone metabolic disease in menopause, and long-term medication is accompanied by serious side effects. Estrogen deficiency-mediated hyperactivated osteoclasts is the initiating factor for bone loss, which is regulated by nuclear factor-κB (NF-κB) signaling. Safranal (Saf) is a monoterpene aldehyde produced from Saffron (Crocus sativus L.) and possesses multiple biological properties, particularly the anti-inflammatory property. However, Saf's role in osteoporosis remains unknown. PurposeThis study aims to validate the role of Saf in osteoporosis and explore the potential mechanism. Study DesignThe RANKL-exposed mouse BMM (bone marrow monocytes) and the castration-mediated osteoporosis model were applied to explore the effect and mechanism of Saf in vitro and in vivo. MethodThe effect of Saf on osteoclast formation and function were assessed by TRAcP staining, bone-resorptive experiment, qPCR, immunoblotting and immunofluorescence, etc. Micro-CT, HE, TRAcP and immunohistochemical staining were performed to estimate the effects of Saf administration on OVX-mediated osteoporosis in mice at imaging and histological levels. ResultsSaf concentration-dependently inhibited RANKL-mediated osteoclast differentiation without affecting cellular viability. Meanwhile, Saf-mediated anti-osteolytic capacity and Sirt1 upregulation were also found in ovariectomized mice. Mechanistically, Saf interfered with NF-κB signaling by activating Sirt1 to increase p65 deacetylation and inactivating IKK to decrease IκBα degradation. ConclusionOur results support the potential application of Saf as a therapeutic agent for osteoporosis.

Tissue transglutaminase exacerbates renal fibrosis via alternative activation of monocyte-derived macrophages

Macrophages are important components in modulating homeostatic and inflammatory responses and are generally categorized into two broad but distinct subsets: classical activated (M1) and alternatively activated (M2) depending on the microenvironment. Fibrosis is a chronic inflammatory disease exacerbated by M2 macrophages, although the detailed mechanism by which M2 macrophage polarization is regulated remains unclear. These polarization mechanisms have little in common between mice and humans, making it difficult to adapt research results obtained in mice to human diseases. Tissue transglutaminase (TG2) is a known marker common to mouse and human M2 macrophages and is a multifunctional enzyme responsible for crosslinking reactions. Here we sought to identify the role of TG2 in macrophage polarization and fibrosis. In IL-4-treated macrophages derived from mouse bone marrow and human monocyte cells, the expression of TG2 was increased with enhancement of M2 macrophage markers, whereas knockout or inhibitor treatment of TG2 markedly suppressed M2 macrophage polarization. In the renal fibrosis model, accumulation of M2 macrophages in fibrotic kidney was significantly reduced in TG2 knockout or inhibitor-administrated mice, along with the resolution of fibrosis. Bone marrow transplantation using TG2-knockout mice revealed that TG2 is involved in M2 polarization of infiltrating macrophages derived from circulating monocytes and exacerbates renal fibrosis. Furthermore, the suppression of renal fibrosis in TG2-knockout mice was abolished by transplantation of wild-type bone marrow or by renal subcapsular injection of IL4-treated macrophages derived from bone marrow of wild-type, but not TG2 knockout. Transcriptome analysis of downstream targets involved in M2 macrophages polarization revealed that ALOX15 expression was enhanced by TG2 activation and promoted M2 macrophage polarization. Furthermore, the increase in the abundance of ALOX15-expressing macrophages in fibrotic kidney was dramatically suppressed in TG2-knockout mice. These findings demonstrated that TG2 activity exacerbates renal fibrosis by polarization of M2 macrophages from monocytes via ALOX15.

Isopsoralen suppresses receptor activator of nuclear factor kappa-β ligand-induced osteoclastogenesis by inhibiting the NF-κB signaling.

Osteoporosis is a serious systemic metabolic bone system disease.This study aimed to identify the target genes of isopsoralen and the signaling pathways involved in the differential expression of the genes involved in osteoclast differentiation. We hypothesized that isopsoralen may inhibit osteoclast differentiation by blocking the nuclear factor kappa-B (NF-κB) signaling pathway and verified our hypothesis through basic experiments. The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to detect the effect of isopsoralen on the proliferation and viability of primary mouse bone marrow monocytes (BMMCs). The effect of isopsoralen on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast differentiation was determined by using tartrate-resistant acid phosphatase (TRAP) staining. Quantitative real-time PCR (qRT-PCR) and Western blot were used to detect the expression of the related genes and proteins. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway of isopsoralen target genes were obtained through comprehensive analysis using the STITCH database, Cytoscape 3.8.2, and R-Studio software. Differentially expressed genes (DEGs) were found in osteoclasts induced by RANKL before and after 3 days using R-Studio, following which KEGG analysis was performed. Next, enrichment analysis was performed on the KEGG pathway shared by the target genes of isopsoralen and the differentially expressed genes during osteoclast differentiation to predict the signaling pathway underlying the inhibition of osteoclast differentiation by isopsoralen. Finally, Western blot was used to detect the effect of isopsoralen on the activation of signaling pathways to verify the results of our bioinformatics analysis. Based on the enrichment analysis of isopsoralen target genes and differentially expressed genes during osteoclastogenesis, we believe that isopsoralen can inhibit RANKL-induced osteoclastogenesis by inhibiting the NF-κB signaling pathway.

Putting PLX5622 into perspective: microglia in central nervous system viral infection.

Putting PLX5622 into perspective: microglia in central nervous system viral infection.